Improving Understanding and Treatment of Rare Diseases through Real-World Data

Abstract

The paper discusses the challenges in developing treatments for rare diseases, such as limited understanding, small patient populations, diagnostic delays, and disease heterogeneity. It emphasizes the role of real-world data in enhancing the understanding of rare diseases by providing insights into natural history, patient populations, treatment effects, biomarker identification, data sharing, and regulatory decision-making. The paper highlights recommendations to improve rare disease research, including promoting data sharing, utilizing advanced technologies, enhancing patient engagement, establishing rare disease registries, and fostering translational research initiatives. By addressing these challenges and implementing these recommendations, the rare disease research community can accelerate scientific discoveries, improve patient outcomes, and transform healthcare for individuals affected by rare diseases.

Keywords: Treatment outcomes, patient engagement, diagnostic delays, data harmonization

1. Introduction and Background

A rare disease, also known as an orphan disease, is a medical condition that has a low prevalence in the population. The exact definition of a rare disease can vary by region, but it is generally characterized by affecting a small number of individuals within a given population. In the United States, a disease is considered rare if it affects fewer than 200,000 individuals. Rare diseases are often complex and heterogeneous, with diverse manifestations and underlying causes. Many rare diseases have a genetic basis, and they can present significant challenges in terms of diagnosis, treatment, and research due to their limited prevalence and the lack of understanding surrounding them^1,2.

Patients with rare diseases often face diagnostic delays, as healthcare providers may not be familiar with these conditions, leading to a prolonged period between the onset of symptoms and receiving a correct diagnosis. Additionally, the development of effective treatments for rare diseases can be challenging due to the small patient populations, limited research funding, and difficulties in conducting clinical trials³.

Efforts to address the challenges associated with rare diseases include initiatives to increase awareness, improve access to information, enhance research collaboration, and develop targeted therapies. Regulatory frameworks such as the Orphan Drug Act in the United States and the Orphan Regulation in the European Union aim to incentivize pharmaceutical companies to develop treatments for rare diseases by providing various benefits and incentives^4,5.

The purpose of this paper is to evaluate the role of real-world datasets in improving the understanding of rare diseases. The paper tries to identify gaps in rare disease research and come up with recommendations to help evolve the rare disease research.  

2. Literature Review

2.1 Challenges in developing treatment for rare disease

Developing treatments for rare diseases presents several challenges due to the unique nature of these conditions. Some of the key challenges in developing treatments for rare diseases include:

• Limited understanding: Rare diseases are often poorly understood, with limited knowledge about their underlying causes, disease mechanisms, and natural history. This lack of understanding can hinder the development of targeted therapies and effective treatment strategies.
• Small patient populations: Rare diseases by definition affect a small number of individuals, making it challenging to conduct clinical trials with an adequate sample size. The small patient populations can also limit the availability of data needed for research and drug development.
• Diagnostic delays: Patients with rare diseases often experience delays in diagnosis due to the rarity of their condition and the lack of awareness among healthcare providers. Diagnostic delays can lead to disease progression and impact the timely initiation of treatment.
• Heterogeneity: Rare diseases encompass a wide range of conditions with diverse manifestations and underlying genetic causes. The heterogeneity of rare diseases can complicate treatment development, as therapies may need to be tailored to specific subtypes or genetic mutations.
• Lack of biomarkers: Many rare diseases lack well-defined biomarkers that can be used to measure disease activity, predict treatment response, or monitor disease progression. The absence of reliable biomarkers can make it challenging to assess the efficacy of potential treatments.
• Limited research funding: Research funding for rare diseases is often limited compared to more common diseases. The scarcity of funding can impede research efforts, hinder the translation of scientific discoveries into clinical applications, and slow down the development of new treatments.
• Recruitment and retention of patients: Recruiting and retaining patients for clinical trials for rare diseases can be difficult due to the small patient populations, geographic dispersion of patients, and the need for specialized expertise in managing these conditions. This can prolong the timeline for drug development and regulatory approval.
• Addressing these challenges requires a collaborative effort among researchers, healthcare providers, patient advocacy groups, policymakers, and pharmaceutical companies. Initiatives to improve data sharing, increase research funding, enhance patient engagement, and streamline regulatory processes can help overcome the obstacles in developing treatments for rare diseases and improve outcomes for patients with these conditions^1-3,6-8.

2.2. Role of real-world data in rare disease understanding

Real-world datasets play a crucial role in enhancing the understanding of rare diseases by providing valuable insights into various aspects of these conditions. Some key roles of real-world datasets in rare disease understanding include:

• Natural history data: Real-world data (RWD) can provide insights into the natural history of rare diseases by capturing information on disease progression, clinical manifestations, treatment patterns, and outcomes in routine clinical practice. Understanding the natural history of rare diseases is essential for developing targeted therapies and improving patient care.
• Patient populations: Real-world datasets can help identify and characterize patient populations affected by rare diseases, including demographic information, comorbidities, genetic profiles, and treatment histories. This information can aid in stratifying patients based on disease subtypes, severity, and response to treatment.
• Treatment effects: Real-world evidence can be used to assess the effectiveness and safety of treatments for rare diseases in real-world clinical settings. By analyzing treatment outcomes, adverse events, and long-term follow-up data, researchers can evaluate the real-world impact of interventions and inform clinical decision-making.
• Biomarker identification: Real-world datasets can facilitate the identification of biomarkers associated with rare diseases by analyzing genetic, clinical, and laboratory data from diverse patient populations. Biomarkers play a critical role in disease diagnosis, prognosis, and treatment response, and real-world data can help validate and refine biomarker candidates.
• Data sharing and collaboration: Real-world datasets enable data sharing and collaboration among researchers, healthcare providers, patient advocacy groups, and pharmaceutical companies. By pooling data from multiple sources, researchers can enhance the statistical power of analyses, validate findings, and generate new hypotheses to advance rare disease research.
• Regulatory decision-making: Real-world evidence can support regulatory decision-making processes by providing additional insights into the safety, effectiveness, and real-world impact of treatments for rare diseases. Regulatory agencies may use real-world data to supplement traditional clinical trial data and inform drug approval and post-market surveillance.
• Real-world datasets play a vital role in advancing the understanding of rare diseases by providing valuable insights into disease progression, patient populations, treatment effects, biomarkers, and real-world outcomes. Leveraging real-world evidence can help address the challenges associated with rare diseases, accelerate research efforts, and improve patient outcomes in this critical area of healthcare^9,10.

2.3. Patient identification in real-world data

Patient identification in real-world datasets for rare diseases is a critical aspect of research and healthcare delivery. Several approaches and considerations are essential for effectively identifying and characterizing patients in these datasets:

• Disease coding and classification: Utilizing standardized disease coding systems such as ICD-10 (International Classification of Diseases, 10th Revision) and Orphanet classification to accurately identify rare diseases in electronic health records (EHRs) and administrative databases. Ensuring that rare disease codes, synonyms, and specific phenotypic features are captured to improve patient identification and data quality.
• Genetic testing and molecular diagnostics: Incorporating genetic testing results, variant data, and molecular diagnostic information to identify patients with rare genetic disorders based on specific gene mutations or variants. Linking genetic data with clinical phenotypes to enhance patient stratification and subgroup identification in real-world datasets.
• Patient registries and disease-specific databases: Leveraging disease-specific patient registries, research databases, and collaborative networks to access detailed clinical information, treatment outcomes, and longitudinal data for rare disease patients. Integrating data from multiple sources to create a comprehensive view of patient characteristics, disease progression, and response to therapies.
• Natural Language Processing (NLP) and Text mining: Applying NLP algorithms and text mining techniques to extract relevant information from unstructured clinical notes, physician narratives, and medical reports in EHRs. Identifying key clinical features, diagnostic criteria, and disease-specific keywords to improve patient identification and phenotype characterization.
• Data linkage and Cross-Referencing: Linking patient data across different datasets, healthcare systems, and research repositories to create a longitudinal patient profile and track healthcare utilization, treatment patterns, and outcomes over time. Cross-referencing patient identifiers, genetic data, and clinical variables to ensure data accuracy, privacy protection, and data harmonization across diverse sources.
• Collaborative data sharing and interoperability: Promoting data sharing initiatives, data harmonization standards, and interoperable platforms to facilitate the exchange of patient data and research findings among institutions, researchers, and healthcare providers. Establishing data sharing agreements, governance frameworks, and ethical guidelines to protect patient privacy, confidentiality, and data security in real-world datasets.

By employing these strategies and technologies, researchers and healthcare professionals can enhance patient identification, data quality, and research insights in real-world datasets for rare diseases. This comprehensive approach enables the effective study of rare diseases, personalized medicine initiatives, and the development of innovative therapies tailored to individual patient needs^9,11,12.

Figure 1: Harmonization of Real-World Datasets⁹

2.4. Recommendations to improve rare disease research

Improving rare disease research requires a multidimensional approach that addresses various challenges in data collection, patient identification, research collaboration, and therapeutic development. Here are some recommendations to enhance rare disease research:

• Enhance Data Sharing and Collaboration: Encourage data sharing initiatives, collaborative research networks, and multi-stakeholder partnerships to facilitate the exchange of data, resources, and expertise in rare disease research. Establish standardized data sharing protocols, interoperable platforms, and governance frameworks to promote transparency, reproducibility, and data harmonization across different datasets.
• Utilize Advanced Technologies: Embrace innovative technologies such as artificial intelligence (AI), machine learning, and data analytics to analyze large-scale datasets, identify disease patterns, and predict treatment outcomes in rare diseases. Implement bioinformatics tools, computational algorithms, and high-throughput sequencing platforms to accelerate genetic discovery, biomarker identification, and drug repurposing efforts.
• Improve Patient Engagement and Advocacy: Involve patients, caregivers, and patient advocacy organizations in research design, clinical trials, and healthcare decision-making to ensure that research priorities align with patient needs and preferences. Empower patients with access to educational resources, support networks, and personalized health information to enhance their participation in research studies and treatment decision-making.
• Establish Rare Disease Registries: Develop comprehensive rare disease registries that capture longitudinal patient data, genetic information, clinical outcomes, and treatment responses to support epidemiological studies, natural history research, and therapeutic development. Harmonize data collection standards, data elements, and data sharing agreements across national and international registries to enable cross-border research collaborations and data exchange.
• Promote Translational Research: Foster translational research initiatives that bridge basic science discoveries with clinical applications to accelerate the development of novel diagnostics, therapies, and precision medicine approaches for rare diseases. Support interdisciplinary research teams, translational research centers, and public-private partnerships to translate scientific insights into tangible benefits for patients and healthcare providers.
• Enhance Regulatory Support: Advocate for regulatory incentives, orphan drug designations, and expedited review pathways to incentivize pharmaceutical companies, biotech firms, and academic researchers to invest in rare disease drug development. Collaborate with regulatory agencies, patient advocacy groups, and industry stakeholders to streamline regulatory processes, improve access to orphan drugs, and promote patient-centered drug development strategies.

By implementing these recommendations, the rare disease research community can overcome existing challenges, accelerate scientific discoveries, and improve the diagnosis, treatment, and quality of life for individuals affected by rare diseases. Collaboration, innovation, patient engagement, and regulatory support are key drivers for advancing rare disease research and transforming healthcare outcomes for rare disease patients^13-15.

3. Conclusion

The paper emphasizes the importance of utilizing real-world datasets to enhance the understanding and treatment of rare diseases. By addressing the challenges faced by patients with rare diseases, such as diagnostic delays and limited research funding, and by implementing recommendations to improve data sharing, collaboration, and the use of advanced technologies, the rare disease research community can accelerate scientific discoveries and improve healthcare outcomes for individuals affected by rare diseases. Collaboration, innovation, patient engagement, and regulatory support are highlighted as key drivers for advancing rare disease research and transforming healthcare outcomes for rare disease patients.

4. References

1. Valdez R, Ouyang L, Bolen J. Public health and rare diseases: Oxymoron no more. Prev Chronic Dis 2016;13: 05.
2. Eurordis. Rare diseases: understanding this public health priority. Eurordis 2005
3. Richter T, Nestler-Parr S, Babela R, et al. Rare disease terminology and definitions-A systematic global review: report of the ISPOR rare disease special interest group. Value Health 2015;18: 906-914.
4. Council of the European Union. Council recommendation on action in the field of rare diseases-2947th employment, social policy, health and consumer affairs-council meeting. Council of the European Union 2009.
5. National Institute of Health. Public Law 97-414 97th Congress. National Institute of Health 1983.
6. Ji X, Liang J, Ji S. Research status in treatment of rare diseases. Chinese Journal of Clinical Pharmacy 2019;35: 115-118.
7. Jiang J, Jing L, Li W. Current views on rare diseases research and orphan drugs development. Journal Bioengineering, 2011;27: 724-729.
8. Kulagin A, Ptushkin V, Lukina E, et al. Phase III clinical trial of Elizaria® and Soliris® in adult patients with paroxysmal nocturnal hemoglobinuria: Results of comparative analysis of efficacy, safety, and pharmacological data. Blood 2019;134: 3748.
9. Liu S, Barrett JS, Leonardi ET, et al. Natural History and Real-World Data in Rare Diseases Applications. J Clin Pharmacol 2022;62: 38-55.
10. Shen F, Zhao Y, Wang L, et al. Rare disease knowledge enrichment through a data-driven approach. BMC Medical Informatics and Decision Making 2019;19.
11. Girman CJ, Ritchey ME, Zhou W, Dreyer NA. Considerations in characterizing real-world data relevance and quality for regulatory purposes: a commentary. Pharmacoepidemiol Drug Saf 2019;28: 439-442.
12. Rubinstein Y. The GRDR-GUID: a model for global sharing of patients de-identified data. Academia 2014.
13. EUCERD. EUCERD core recommendations on rare disease patient registration and data collection. EUCERD 2013.
14. Commission Expert Group on Rare Diseases. Recommendation on ways to improve codification for rare diseases in health information systems. 2014.
15. RD-Action. Overview report on the state of the art of rare disease activities in Europe. RD-Action, 2018.